Neurocrine Biosciences Stock Forecast, Price & News NASDAQ:NBIX

According to 22 analysts, the average rating for NBIX stock is “Buy.” The 12-month stock price forecast is $127.73, which is an increase of 12.26% from the latest price. Netflix reported revenues of $8.19 billion in the last reported quarter, representing a year-over-year change of +2.7%. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories.

Neurocrine Biosciences’ stock is owned by many different retail and institutional investors. 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company’s employees.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.

• The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $127.63 average price target.
• Neurocrine Biosciences has generated $1.73 earnings per share over the last year ($1.73 diluted earnings per share) and currently has a price-to-earnings ratio of 65.8.
• See which 3 stocks are most likely to make moves following their insider activities.
• The company expects to have its pediatric results in the fourth quarter.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $127.63 average price target. According to TipRanks, Shibutani is a 5-star analyst with an average return of 20.6% and a 44.25% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Exelixis, Neurocrine, and Revance Therapeutics. The technique has proven to be very useful for finding positive surprises.

Neurocrine Biosciences stock price target cut to $117 from $132 at Mizuho

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder linked with Huntington’s disease…

The consensus among Wall Street research analysts is that investors should “moderate buy” NBIX shares. Without considering a stock’s valuation, no investment decision can be efficient. In predicting a stock’s future price performance, it’s crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company’s growth prospects. For the current fiscal year, the consensus earnings estimate of $11.92 points to a change of +19.8% from the prior year.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of NBIX stock can currently be purchased for approximately $113.77. Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences Inc’s Meteoric Rise: Unpacking the 22% Surge in Just 3 Months

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, NBIX info will be updated daily in your Zacks.com Portfolio Tracker – also free.

We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of NBIX’s
competitive advantage.

Neurocrine Biosciences Scores Relative Strength Rating Upgrade; Hits Key Benchmark

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical ticker tape coupon portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Netflix is rated Zacks Rank #3 (Hold).

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Neurocrine Biosciences, Inc.

Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets. Over the last four quarters, Netflix surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.

This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. Sign-up to receive https://1investing.in/ the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat’s FREE daily newsletter. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results

Netflix is expected to post earnings of $3.49 per share for the current quarter, representing a year-over-year change of +12.6%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.3%. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Compare
NBIX’s historical performance
against its industry peers and the overall market. NBIX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying attention to the market buzz about Netflix. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Netflix is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Compared to the Zacks Consensus Estimate of $8.26 billion, the reported revenues represent a surprise of -0.93%.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Neurocrine Biosciences’s earnings are expected to grow from $2.17 per share to $4.87 per share in the next year, which is a 124.42% increase. In Neurocrine’s study, adults with CAH who took crinecerfont had a statistically significant decrease in their daily glucocorticoids dosage, while still keeping their androgen levels under control. Traditionally, managing CAH requires daily doses of steroid hormones called glucocorticoids and suppressing androgen hormones. Left unchecked, children with CAH could produce too much testosterone, leading to rapid growth and early puberty.